| Bristol-Myers Squibb Co. | (NY: BMY) |
|
USD
|
|
Official Closing Price
/ Updated: /
|
| View: | Quote | News | Research |
|
97%
agree
36 votes
|
"Good strategic direction for continued, efficient, research and development" |
|
100%
agree
9 votes
|
MarketGrader.Com Score 66.6 Buy |
|
68%
agree
16 votes
|
BMY an acquisition target? |
|
16%
agree
6 votes
|
Few to no products in early development or testing |
|
27%
agree
11 votes
|
If a stock is "cheap" there has to be a reason why. |
|
0%
agree
5 votes
|
The Plavix situation |
May 23, 2013
This article is about Bristol-Myers Squibb. For the article on the company with ticker BMS, see Bemis Company (BMS).
Bristol-Myers Squibb (NYSE: BMY) is one of the world's largest pharmaceutical companies by total sales. Bristol-Myers Squibb offers treatments for cardiovascular disease, HIV/AIDS, hepatitis, cancer, and rheumatoid arthritis. Cancer treatments in particular represent a major portion of the company's long-term growth potential and have historically been a strong suit of Bristol-Myers Squibb. The company's top three blockbuster drugs (annual sales >$1 billion) are blood thinner Plavix, Abilify for schizophrenia, and Reyataz for HIV. In FY 2010, BMY generated revenues of $19.5B and net earnings of $3.1B.[1]
(Read more at Wikinvest
) 
